Publication: 3481

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
      Google Scholar   
Citation:
Blood vol 139 (8) 1147-59
Year:
2022
Type:
Manuscript
Funding:
AFT
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
11
Parents:
2833   2997  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
Bristol-Myers Squibb, Celegene  
Grants:
 
Corr. Author:
 
Authors:
                           
Networks:
FL065, FL310, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, NY018, RI005, TX041   
Study
AFT-08
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: